KEYDP/TEXAS BIOTECHNOLOGY SIGN RESEARCH PACT.Key Drug Prototyping BV (KeyDP), Leiden, The Netherlands, a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , and Texas Biotechnology Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :TXBI) have signed a research agreement wherein KeyDP will develop protein structures for several proprietary inhibitors that have been identified by Texas Biotechnology. KeyDP will provide its expertise in X-ray crystallography X-ray crystallography, the study of crystal structures through X-ray diffraction techniques. When an X-ray beam bombards a crystalline lattice in a given orientation, the beam is scattered in a definite manner characterized by the atomic structure of the lattice. to generate the protein structures and will receive development fees, milestone payments and royalty payments on products that may be commercialized as a result of this alliance. Flip J. Hoedemaeker Ph.D., president of KeyDP, stated, "Texas Biotechnology's scientists are recognized for their expertise in identifying targets that play a meaningful role in several diseases. Their experience, combined with our expertise in X-ray crystallography, represents a highly synergistic and focused alliance." Richard A.F. Dixon, Ph.D., senior vice president and chief scientific officer of Texas Biotechnology, stated, "This alliance expands our internal research capabilities and allows us access to proprietary structural information on several key target proteins. We are confident that this alliance will accelerate our drug discovery and development process." Texas Biotechnology, a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for its expertise in small molecule drug development and vascular biology. Argatroban, its first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia heparin-induced thrombocytopenia Acquired thrombocytopenia affecting some heparin-treated Pts–HTPs, defined as a ↓ platelet count during or shortly after heparin exposure; HIT is a markedly prothrombotic disorder seen in Pts who are at a high baseline . Additional studies are underway to support the use of Argatroban in ischemic stroke Noun 1. ischemic stroke - the most common kind of stroke; caused by an interruption in the flow of blood to the brain (as from a clot blocking a blood vessel) ischaemic stroke , angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. and hemodialysis. Texas Biotechnology also has two highly selective endothelin A receptor antagonists in clinical development for pulmonary arterial hypertension and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. . KeyDP is in business to develop new drugs based on the atomic details of carefully selected protein targets with good drug potential. Their technology development focuses on facilitating all aspects of structure-aided drug discovery. To this aim, KeyDP establishes strategic partnerships to complement its own focus on the molecular aspects of drug design and development. For more information, visit http://www.tbc.com and http://www.keydp.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion